Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma

Kara M. Kelly; David Hodgson; Burton Appel; Lu Chen; Peter D. Cole; Terzah Horton; Frank G. Keller

doi:10.1002/pbc.24423

Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma

Kara M. Kelly, David Hodgson, Burton Appel, Lu Chen, Peter D. Cole, Terzah Horton, Frank G. Keller

Pediatrics

Research output: Contribution to journal › Review article › peer-review

52 Scopus citations

Abstract

In childhood Hodgkin lymphoma, estimated 5 years survival rates exceed 90%. Long-term survival continues to decline from delayed toxicities. Key findings from recent Children's Oncology Group trials include: (1) Radiotherapy selection may be based on early chemotherapy response assessed by both FDG-PET and CT imaging, (2) A new prognostic factor score stratifies patients into risk categories; and (3) novel retrieval regimens were identified. A phase I/II trial is investigating Brentuximab vedotin (Bv) with gemcitabine in relapsed patients. A phase 3 trial will modify conventional chemotherapy and radiotherapy approaches through the addition of Bv, while incorporating translational biology to identify molecular targets.

Original language	English (US)
Pages (from-to)	972-978
Number of pages	7
Journal	Pediatric Blood and Cancer
Volume	60
Issue number	6
DOIs	https://doi.org/10.1002/pbc.24423
State	Published - Jun 2013

Keywords

Biomarkers
Children
Clinical trials
Hodgkin lymphoma
Malignancies

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.24423

Cite this

@article{1eb11642f4414cba8bb6806afed35ef0,

title = "Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma",

abstract = "In childhood Hodgkin lymphoma, estimated 5 years survival rates exceed 90%. Long-term survival continues to decline from delayed toxicities. Key findings from recent Children's Oncology Group trials include: (1) Radiotherapy selection may be based on early chemotherapy response assessed by both FDG-PET and CT imaging, (2) A new prognostic factor score stratifies patients into risk categories; and (3) novel retrieval regimens were identified. A phase I/II trial is investigating Brentuximab vedotin (Bv) with gemcitabine in relapsed patients. A phase 3 trial will modify conventional chemotherapy and radiotherapy approaches through the addition of Bv, while incorporating translational biology to identify molecular targets.",

keywords = "Biomarkers, Children, Clinical trials, Hodgkin lymphoma, Malignancies",

author = "Kelly, {Kara M.} and David Hodgson and Burton Appel and Lu Chen and Cole, {Peter D.} and Terzah Horton and Keller, {Frank G.}",

year = "2013",

month = jun,

doi = "10.1002/pbc.24423",

language = "English (US)",

volume = "60",

pages = "972--978",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "6",

}

TY - JOUR

T1 - Children's Oncology Group's 2013 blueprint for research

T2 - Hodgkin lymphoma

AU - Kelly, Kara M.

AU - Hodgson, David

AU - Appel, Burton

AU - Chen, Lu

AU - Cole, Peter D.

AU - Horton, Terzah

AU - Keller, Frank G.

PY - 2013/6

Y1 - 2013/6

N2 - In childhood Hodgkin lymphoma, estimated 5 years survival rates exceed 90%. Long-term survival continues to decline from delayed toxicities. Key findings from recent Children's Oncology Group trials include: (1) Radiotherapy selection may be based on early chemotherapy response assessed by both FDG-PET and CT imaging, (2) A new prognostic factor score stratifies patients into risk categories; and (3) novel retrieval regimens were identified. A phase I/II trial is investigating Brentuximab vedotin (Bv) with gemcitabine in relapsed patients. A phase 3 trial will modify conventional chemotherapy and radiotherapy approaches through the addition of Bv, while incorporating translational biology to identify molecular targets.

AB - In childhood Hodgkin lymphoma, estimated 5 years survival rates exceed 90%. Long-term survival continues to decline from delayed toxicities. Key findings from recent Children's Oncology Group trials include: (1) Radiotherapy selection may be based on early chemotherapy response assessed by both FDG-PET and CT imaging, (2) A new prognostic factor score stratifies patients into risk categories; and (3) novel retrieval regimens were identified. A phase I/II trial is investigating Brentuximab vedotin (Bv) with gemcitabine in relapsed patients. A phase 3 trial will modify conventional chemotherapy and radiotherapy approaches through the addition of Bv, while incorporating translational biology to identify molecular targets.

KW - Biomarkers

KW - Children

KW - Clinical trials

KW - Hodgkin lymphoma

KW - Malignancies

UR - http://www.scopus.com/inward/record.url?scp=84876452914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876452914&partnerID=8YFLogxK

U2 - 10.1002/pbc.24423

DO - 10.1002/pbc.24423

M3 - Review article

C2 - 23255501

AN - SCOPUS:84876452914

SN - 1545-5009

VL - 60

SP - 972

EP - 978

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 6

ER -

Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this